Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 14, 2026International Journal of Innovative Technologies in Social ScienceOpen Access

Effectiveness and Safety of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Real-World Practice: A Systematic Review

View Full Paper
Ask AI
Bookmark
Share

Authors

DSDawid StudzinskiMSMandy SchulzKOKarolina Osińska

Discussion

Loading...

Member takes

Overview

Systematic review evaluates real-world safety and efficacy of CGRP inhibitors in migraine prevention, indicating durability and safety.

Key Points

  • This review assesses the real-world effectiveness and safety of anti-CGRP monoclonal antibodies for migraine prevention.
  • Conducted a systematic search of PubMed (2021–2026) for observational studies and registries.
  • Synthesized findings from 32 studies involving over 1 million patients.
  • Analyzed data regarding erenumab, fremanezumab, galcanezumab, and eptinezumab.
  • Sustained responder rates of ≥ 50% in most cohorts (40%–75%) for migraine prevention.
  • Significant reduction in acute medication use after treatment.
  • No increased risk of myocardial infarction or stroke compared to onabotulinumtoxinA, even in older adults.

Cite This Study

Studzinski et al. (2026) studied this question.

synapsesocial.com/papers/6a2e4524b1cc60ccdea8a74fhttps://doi.org/10.31435/ijitss.2(50).2026.5396
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cgrp Monoclonal Antibodies: Key Lessons from Real World Evidence2024 · 4 citations
  2. 2Patient Adherence and Long-Term Tolerability of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention: A Systematic Review2025 · 2 citations
  3. 3Efficacy and safety of CGRP monoclonal antibodies in chronic migraine: a systematic review integrating randomized and real-world evidence2026
  4. 4Real world effectiveness of anti-CGRP monoclonal antibodies over three consecutive one-year treatment cycles: An intention-to-treat analysis2025 · 5 citations
  5. 5Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group2026